ReviewFrontiers in immunology2026
Research progress in intratumoral microbiota: unlocking the potential of cancer immunotherapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, intratumoral microbiota (ITM), a crucial component of the tumor microenvironment, have received increasing attention because of their role in cancer immunotherapy. ITM not only influence tumor initiation and progression but also modulate local and systemic immune responses, thereby affecting the efficacy of immune checkpoint inhibitors and other immunotherapeutic approaches. This review summarizes the compositional characteristics of ITM, their immunoregulatory mechanisms, and their effects on tumor metastasis and responsiveness to immunotherapy. Particular emphasis is placed on interactions between intratumoral microbiota and immune therapies across cancer types, highlighting potential therapeutic strategies that exploit these microbial influences. Furthermore, the review discusses current challenges in integrating intratumoral microbiota into immunotherapeutic paradigms and outlines future research directions. By providing a comprehensive overview of the role of ITM in cancer immunity, this review aims to support advances in precision oncology and foster novel approaches to enhance immunotherapy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.